Linde Submits NOxBox I Plus for FDA Clearance
Linde Gas & Equipment Inc has submitted a 510(k) premarket notification to the FDA for its NOxBox I Plus, a nitric oxide delivery and monitoring system.
Tag: inhaled nitric oxide
All
Latest
Linde Submits NOxBox I Plus for FDA Clearance
Linde Gas & Equipment Inc has submitted a 510(k) premarket notification to the FDA for its NOxBox I Plus, a nitric oxide delivery and monitoring system.
Read More
LungFit PH Receives Market Authorization in Australia
Beyond Air’s LungFit PH has received market authorization from the Australian Therapeutic...
Read More
Wisconsin Hospital Becomes First to Implement New Nitric Oxide Delivery System
The hospital is using the INOmax Evolve DS system, a nitric oxide delivery device used with mechanical ventilation for critically ill patients.
Read More
Mallinckrodt Expands Rollout of INOmax Evolve DS
Mallinckrodt has begun a national rollout of the INOmax Evolve DS delivery system, which is FDA-cleared to provide inhaled nitric oxide to certain neonatal ICU patients in order to improve oxygenation and reduce the need for extracorporeal membrane oxygenation.
Read More
Unmasking Undiagnosed Asthma and COPD Improves Health
Identifying and treating people with previously undiagnosed asthma or COPD led to improved respiratory symptoms, quality of life, and reduced healthcare visits in the year after diagnosis.
Read More
High-dose Inhaled Nitric Oxide Decreased ARDS-related Mortality Risk in Black Patients with COVID-19
High-dose inhaled nitric oxide (iNO) therapy may improve oxygenation and reduce the risk of ARDS-related mortality among critically ill Black patients with COVID-19, according to a first-of-its-kind study published in the American Journal of Respiratory and Critical Care Medicine.
Read More
FDA Clears INOmax Evolve DS
The INOmax Evolve DS is Mallinckrodt’s next-generation nitric oxide delivery system that includes a primary delivery system, a monitoring system, an electronic blender, automated backup delivery, mini-cylinders, and more.
Read More
High-dose Inhaled Nitric Oxide Aids COVID-19 Respiratory Failure
A phase 2 study showed the treatment improved blood oxygen levels and lowered the risk of long-term sensory and motor neurologic symptoms.
Read More
Mallinckrodt Recalls One-Way Valve Due to Ventilation Interruption Risk
Mallinckrodt Manufacturing is recalling its one-way valve, 22F x 22M, due to devices not opening properly, which prevents or reduces the flow of ventilated air or oxygen.
Read More
NOxBOXi Nitric Oxide Systems Recalled
The recall was issued due to a misalignment of the check valve in the device’s manifold, which may cause the manifold to fail and interrupt therapy to neonates.
Read More
RT 2023 Product Focus: The Digital Edition
RT’s 2023 Product Focus provides a detailed look at 42 of the newest medical devices, including 18 exclusive products not available in the print edition.
Read More
Market Analysis: The Impact of Cylinder-free Systems on Inhaled Nitric Oxide Delivery
RT magazine spoke with manufacturers of inhaled nitric oxide delivery systems about the latest market innovations in the iNO industry, specifically about the impact of cylinder-free (“tankless”) systems, plus research on its potential use to treat other cardiopulmonary diseases.
Read More
RT 2023 January-February: The Digital Edition
In RT’s January-February 2023 issue, RTs offer 5 tips for measuring spirometry and 8 considerations for delivering oxygen therapy to COPD patients; airway clearance options for bronchiectasis; and cylinder-free solutions for nitric oxide delivery.
Read More
3rd Generation Tankless Inhaled Nitric Oxide System Gets FDA Approval
The US FDA has approved the third Generation Genosyl Delivery System, a tankless inhaled nitric oxide (iNO) therapy device, according to manufacturer Vero Biotech Inc.
Read More
RT 2022 October-November: The Digital Edition
In RT’s October-November 2022 issue, we cover proper tracheostomy care techniques; endotracheal suctioning in the NICU/PICU; accurate interpretation of arterial blood gases; and inhaled nitric oxide delivery.
Read More
Inhaled Nitric Oxide Delivery: Past, Present, and Future
Inhaled nitric oxide has been utilized as a pulmonary vasodilator for over 20 years and research is ongoing to uncover the usefulness of iNO in several lung diseases and disorders.
Read More
Mallinckrodt Submits iNO Delivery System for FDA Clearance
Mallinckrodt plc reports the submission of a 510(k) premarket notification application to the US FDA for an investigational inhaled nitric oxide delivery system for INOmax (nitric oxide) gas, for inhalation.
Read More
Inhaled Nitric Oxide Reduced Hospital Stay and Supplemental Oxygen Use in Pregnant Women with COVID-19 Pneumonia
High-dose inhaled nitric oxide led to more rapid weaning from supplemental oxygen and reduced length of hospital stay in pregnant women hospitalized with severe COVID-19 pneumonia, according to a study published in Obstetrics & Gynecology.
Read More
Study Evaluates Inhaled Nitric Oxide for COVID-19
Researchers assessed outcomes of INOmax inhaled nitric oxide for COVID-19 patients hospitalized with mild-to-moderate ARDS.
Read More
Inhaled Nitric Oxide in Cardiovascular Surgery for Perioperative Pulmonary Hypertension: A Review
Clinical trial and real-world data provide evidence that inhaled nitric oxide is effective for reducing pulmonary hypertension in the perioperative setting.
Read More
High Concentration Inhaled Nitric Oxide Effectively Self-Administered At-home for NTM Lung Disease
At-home, self-administered high concentration inhaled nitric oxide at home to treat severe nontuberculous mycobacterial (NTM) lung disease was well tolerated with no serious adverse events.
Read More
Developing a Nitric Oxide Therapy for COVID-19, Other Infectious Diseases
Claritas Pharma is developing a nitric oxide-releasing compound that could potentially be administered orally, via nasal spray, or injection, and fight viral infections like SARS-CoV-2.
Read More
Transport of Newborns on Inhaled Nitric Oxide: Logistics, Safety, New FDA Approval
The interhospital transport of infants with persistent pulmonary hypertension of the newborn (PPHN) being administered inhaled nitric oxide therapy requires specialized, intensive care.
Read More
Phase 3 Study Underway for Inhaled Nitric Oxide Treatment of Interstitial Lung Disease
The first patient has been enrolled in Bellerophon’s Phase 3 study of pulsed inhaled nitric oxide to treat fibrotic interstitial lung disease.
Read More